Navigation Links
Wyeth to Invest $280 Million to Build State-of-the-Art Nutritional Manufacturing Facility in China
Date:3/10/2008

uations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

For more information, visit http://www.Wyeth.com


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Wyeth and Nycomed Announce Court Denial of Preliminary Injunction
2. Wyeths Pearl River, N.Y. Facility Celebrates 100 Years of Achievements in Health care
3. Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
4. Wyeth Announces the Election of Robert M. Amen to Its Board of Directors
5. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
6. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
7. Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. Wyeth Consumer Healthcare Announces the Availability of Centrum Cardio and New Formula Centrum Products
10. Wyeth to Present at the Credit Suisse First Boston Healthcare Conference
11. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ctors of Sir Sunderlal hospital in the Banaras Hin...strike// for the second consecutive day today to p...the backward castes in the higher education instit...trike, the agitating doctors formed human chain ou...
...was said that 44 % of women suffer from Intimate P...ffects both the mental health as well as the physi... by senior investigators of the Group Health Cente...alyzed 3,400 women members. The researchers found ...
...ring the routine blood analysis among dialysis pat...patients are estimated to have acquired hepatitis....s or razors with family members, and to use condom...rded says Dr. Michael Finkelstein, an associate me...
...dy it was found that if hearing problems were dete... in learning language as they grow.// They analyse...t. Then it was found that those whose hearing prob... language skills than those born when screening wa...
Other Medicine News:
(Date:9/4/2008)... SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCa...y announced that the pivotal clinical study of,Pol...s partner, Chemische,Fabrik KREUSSLER & Co. GmbH (...point and has been submitted to FDA as part of a N...l clinical study, named the EASI (Efficacy and saf...
(Date:9/4/2008)... Pivotal Study Seeks to Enroll 750 Women at More T.... 4 /- QuatRx Pharmaceuticals, a,priv...velopment and,commercialization of compounds to tr...ers, today announced that it has initiated a secon... tablets), the company,s,estrogen-free oral therap...
(Date:9/4/2008)... Data Announcements Remain on Schedule with Two ... Clinical Data Release in November 2008, BRIDGEWA...ceuticals,Inc., a specialty pharmaceutical compan...etabolic disease, today announced the appointment ... of directors., Peter Garrambone,s career include...
(Date:9/3/2008)... - Long term follow up results from chronically...d exceed positive data obtained earlier in 2008, ...ificant and long-term antiviral effect of t...the way and strongly support move into a second ge...uvant IC31(R) acting through TLR ...
Breaking Medicine Technology:338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Batman Takes on Gotham City With a Little Help From Milk 20428 1Batman Takes on Gotham City With a Little Help From Milk 20428 2Texas Jury Awards 24250 Million Patent Infringement Verdict Against Boston Scientific in Balloon Catheter Lawsuit 20425 1Texas Jury Awards 24250 Million Patent Infringement Verdict Against Boston Scientific in Balloon Catheter Lawsuit 20425 2Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 1Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 2Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 3Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 4Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 5Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen New Survey Reveals 20422 6New Research and Treatment Options for Millions Suffering Headaches and Chronic Pain to be Presented at 10th Annual Headache and Pain Conference 20419 1New Research and Treatment Options for Millions Suffering Headaches and Chronic Pain to be Presented at 10th Annual Headache and Pain Conference 20419 2New Research and Treatment Options for Millions Suffering Headaches and Chronic Pain to be Presented at 10th Annual Headache and Pain Conference 20419 3
...ISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNew...developing Anticalins(R), a,novel class of targete... its proprietary Duocalin(R) technology has succes...mmenting on this development, Dr Andreas Hohlbaum,...f Pieris said: "As Pieris,continues to validate th...
...NTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- ...will present Phase 2,data from its Unit Dose Budes...ram at the World Asthma Meeting at the Lutfi Kirda...rkey. , The oral and poster presentation entitled,...e formulation of budesonide for,nebulized delivery...
Other Medicine Technology:Pieris Progresses Development of its Proprietary Biotherapeutics,Platform: Successful Demonstration of Dual Targeting With,Duocalin(R) Technology 2Pieris Progresses Development of its Proprietary Biotherapeutics,Platform: Successful Demonstration of Dual Targeting With,Duocalin(R) Technology 3MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2
...e DexCom STS Continuous Glucose Monitoring System ...elessly transmits blood glucose readings to the De...ludes a wirelike sensor which is inserted via the ...t under the skin where it is held in place by an a...
...rdioVault combines proven Eclipse,Plus or 850 EC...capability. Doctors,maintain all the benefits of...he,ability to view and access diagnostic-quality...iagnostic-quality viewing and printing,either f...
For practices performing routine Holter,monitoring, the Burdick Vision Holter,System with QuickStep Wizard provides a,practical, no-nonsense diagnostic tool ideal,for todays tightly managed h
For practices that need an advanced Holter,monitoring solution, the Burdick Vision,Premier Holter System provides a powerful,diagnostic tool. The Vision Premier system,adds expanded viewing c
Medicine Products: